Mein Warenkorb

MR1 & B2M

MR1 & B2M Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag & Avi Tag (1)

  • Marker

    Biotin-labeled (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
MRM-H82W5
Human
HEK293
Biotinylated Human MR1&B2M Complex Protein (MALS verified) In den Warenkorb legen
Gesamtmenge1
  • 1

MR1 & B2M Molekülhintergrund

MR1 is also knwon as MHC class I-related gene protein. Antigen-presenting molecule specialized in displaying microbial pyrimidine-based metabolites to alpha-beta T cell receptors (TCR) on innate-type mucosal-associated invariant T (MAIT) cells. In complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1-2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers. Signature pyrimidine-based microbial antigens are generated via non-enzymatic condensation of metabolite intermediates of the riboflavin pathway with by-products arising from other metabolic pathways such as glycolysis. Typical potent antigenic metabolites are 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), products of condensation of 5-amino-6-D-ribityaminouracil (5-A-RU) with glyoxal or methylglyoxal by-products, respectively.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
NidanilimabCAN-04Phase 2 ClinicalLund University FoundationSolid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
CCTx-001CCTx-001Phase 2 ClinicalAdvesya SASLeukemia, Myeloid, Acute
Details
SAR-445399SAR-445399Phase 1 ClinicalSanofiInflammation
Details
GSK3903371GSK3903371ClinicalGlaxosmithkline PlcNeoplasms
Details
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns